Recursion Pharmaceuticals Inc.
Rating
Updated: Aug 14, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes,...
Latest News
1 day ago · businesswire.com
Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion's RNA Foundation ModelCHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). Additionally, the two companies have entered into a new agreement under which Tempus will license Recursion's RNA Foundation Model. Tempus and Recursion have extended their multi-year data partnership through November 2029. The companies share a mission to use foundation models to advance precision medicine, and entered into a co.
5 days ago · zacks.com
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to KnowIn the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.18, marking a -1.85% move from the previous day.
7 days ago · seekingalpha.com
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptRecursion Pharmaceuticals, Inc. (RXRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
12 days ago · zacks.com
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market TodayRecursion Pharmaceuticals (RXRX) concluded the recent trading session at $3.16, signifying a -1.71% move from its prior day's close.
18 days ago · zacks.com
Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report?Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock?
19 days ago · zacks.com
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook?Recursion Pharmaceuticals is expanding its clinical pipeline across oncology and rare diseases, with REC-4881 and multiple programs offering potential growth catalysts.
1 month ago · defenseworld.net
Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline UpdatesRecursion Pharmaceuticals (NASDAQ: RXRX) is using artificial intelligence to generate and analyze biological data in an effort to improve drug discovery, advance internal therapeutic programs and support collaborations with larger pharmaceutical companies, CFO and President of Recursion U.K. Ben Taylor said during a BofA Global Research virtual conference. Taylor described AI not as a "magic wand,"
1 month ago · seekingalpha.com
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference TranscriptRecursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Transcript
1 month ago · seekingalpha.com
Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech NewsRecursion Pharmaceuticals, Inc. remains a Hold as competitive advances and slow revenue growth challenge its AI-driven drug discovery ambitions. RXRX's partnerships, notably with Genentech/Roche and Sanofi, have delivered $500M+ in milestone payments, but further commercial validation is pending. The internal pipeline, led by REC-4881 for FAP, potentially lags competitors (more data is required) and is unlikely to generate significant revenue before 2030.
2 months ago · zacks.com
RXRX Q2 Earnings Miss Estimates, Revenues Fall Y/Y, Stock DownRecursion misses Q2 earnings and revenue estimates as collaboration revenues fall year over year, sending shares lower while pipeline and partnership programs advanced.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove RXRX